Physician profile
Scott Bosy
NPI 1841618717
$1,566.47
in general payments reported to CMS, 2019-2025
22 companies · $819 in 2025
The $819 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.73 · 2020: $73.86 · 2021: $163 · 2022: $106 · 2023: $217 · 2024: $120 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,156.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $284.39 | 2019-2024 | Lifevest |
| Glaxosmithkline, LLC. | $247.80 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Tactile Systems Technology INC | $112.48 | 2024 | Entre Plus, Flexitouch Plus |
| Impulse Dynamics (USA) INC. | $107.90 | 2023 | Optimizer |
| Novo Nordisk INC | $99.43 | 2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $75.41 | 2022-2025 | Breztri, Farxiga |
| Phathom Pharmaceuticals, INC. | $74.55 | 2025 | Voquezna |
| Amgen INC. | $70.73 | 2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $63.27 | 2025 | |
| Eisai INC. | $56.97 | 2025 | |
| Lilly USA, LLC | $42.30 | 2025 | Mounjaro, Zepbound, Kisunla |
| Janssen Pharmaceuticals, INC | $42.20 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $39.01 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.41 | 2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $37.54 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $34.01 | 2025 | |
| Sanofi-Aventis U.S. LLC | $33.56 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.60 | 2025 | Trintellix |
| Insmed, INC. | $23.68 | 2025 | Brinsupri, Arikayce |
| Inspire Medical Systems, INC. | $18.59 | 2025 | Inspire |
| Abbott Laboratories | $17.16 | 2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $16.48 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Bosy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.